The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market During The Forecast Period?
The market size for in vitro diagnostic (ivd) in cardiology and neurology has experienced significant growth over recent years. It is anticipated to expand from $17.22 billion in 2025 to $18.71 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 8.7%. This historical growth can be ascribed to factors such as the increasing prevalence of cardiovascular diseases, the rising incidence of neurological disorders, the expansion of hospital diagnostic infrastructure, advancements in immunoassay technologies, and heightened clinical awareness concerning early diagnosis.
The in vitro diagnostic (ivd) in cardiology and neurology market size is projected to experience robust expansion over the coming years. This market is forecast to reach $25.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the forecast period is primarily driven by factors such as an aging worldwide population, a surging need for personalized diagnostics, the proliferation of point-of-care testing facilities, escalating healthcare spending in developing economies, and the increasing uptake of molecular diagnostics. Key trends anticipated within this period encompass a heightened demand for detecting diseases early, the expanding use of point-of-care cardiac and neuro tests, the broadening scope of biomarker-based diagnostics, an intensified emphasis on preventive and predictive testing, and the incorporation of multi-parameter diagnostic panels.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Drivers Are Supporting The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Growth?
The advancement of personalized medicine is anticipated to propel the growth of the in vitro diagnostic (IVD) in cardiology and neurology market moving forward. Personalized medicine describes a medical approach that customizes healthcare decisions, practices, interventions, and treatments to the unique characteristics of each patient. Its expansion is attributed to factors like progress in genomics, enhanced understanding of disease mechanisms, patient demand for tailored treatments, and regulatory support, among others. In vitro diagnostic (IVD) tests in cardiology and neurology contribute to personalized medicine by supplying vital information about an individual’s genetic composition and disease status, thereby guiding customized treatment plans for improved effectiveness and reduced risks. For example, in February 2024, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization. This marked an increase from six approvals in 2022, with the 2023 approvals also comprising seven oncology therapies and three treatments targeting various other conditions. Hence, the increasing volume of personalized medicines is a key driver for the expansion of the in vitro diagnostic (IVD) in cardiology and neurology market.
Which Segment Types Are Examined In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Segment Study?
The in vitro diagnostic (ivd) in cardiology and neurology market covered in this report is segmented –
1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies
3) By End-User: Hospitals, Clinical Laboratories, Other End-Users
Subsegments:
1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices
2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables
3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services
Which Trends Are Expected To Impact The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
Leading companies operating within the in vitro diagnostic (IVD) market for cardiology and neurology are concentrating on creating AI-enabled integrated epigenetic engines aimed at early disease detection and risk assessment. These AI-powered integrated epigenetic engines utilize machine-learning models and advanced biomarker analysis techniques to elevate the sensitivity and accuracy in diagnosing and monitoring cardiovascular diseases, thereby tackling critical factors contributing to disease progression. As an example, in February 2023, Cardio Diagnostics Holdings Inc., a US-based biotechnology company, introduced PrecisionCHD, an AI-based blood test specifically engineered for the early identification of coronary heart disease (CHD). Employing the company’s integrated epigenetic-genetic engine, this test assesses CHD risk and endeavors to prevent and detect the most common form of cardiovascular disease. This novel test integrates epigenetic and genetic biomarkers with machine-learning algorithms, achieving over 75% sensitivity for both men and women. It establishes a connection between a patient’s biomarker profile and modifiable risk factors, which are significant contributors to CHD, such as smoking, diabetes, hypertension, and high cholesterol. PrecisionCHD offers a non-invasive substitute for exercise stress tests or angiograms, with blood samples collectable either in a medical office or at home.
Which Players Are Part Of The Competitive Landscape Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
Major companies operating in the in vitro diagnostic (ivd) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience
Get The Full In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report:
Which Region Represents The Largest Share Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (ivd) in cardiology and neurology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market 2026, By The Business Research Company
Bioinformatics In In Vitro Diagnostics Ivd Testing Market Report 2026
In Vitro Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report
In Vitro Diagnostics Ivd Quality Control Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model